Print

FibroGen, Inc. Announces Results Showing That FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Corrects Anemia Without Intravenous Iron Supplementation in Incident Dialysis Patients  
11/5/2012 9:56:59 AM

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced preliminary clinical findings from an ongoing open-label Phase 2 study demonstrating the safety and efficacy of FG-4592, investigational oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in the correction of anemia in patients with end-stage renal disease who recently started dialysis with no iron, with oral iron, or with intravenous (IV) iron supplementation.
//-->